WARREN ROOT: Open Payments
NPI 1639192438 · LAFAYETTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$476 in 25 payments from 13 companies in 2025. Trend: 2023 $1,246 · 2024 $754 · 2025 $476
Food & beverage: $476
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $52 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Lundbeck LLC | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| PFIZER INC. | 1 | $24 |
| Exact Sciences Corporation | 1 | $19 |
Products named: Kerendia, VRAYLAR, XIFAXAN, MOUNJARO, REXULTI, CAPLYTA, FARXIGA, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
